Comparative Pharmacology
Head-to-head clinical analysis: DESLORATADINE versus KETOTIFEN FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESLORATADINE versus KETOTIFEN FUMARATE.
DESLORATADINE vs KETOTIFEN FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desloratadine is a long-acting tricyclic histamine antagonist selective for the H1 receptor, inhibiting histamine release from mast cells and basophils. It reduces allergic inflammation by decreasing cytokine and chemokine release.
Antihistamine and mast cell stabilizer; inhibits release of histamine and other mediators from mast cells; also blocks histamine H1 receptors.
5 mg orally once daily.
1 mg orally twice daily; ophthalmic: 1 drop in each eye every 8-12 hours.
None Documented
None Documented
Terminal half-life 27 hours (range 21–30 h) in healthy adults; supports once-daily dosing.
Clinical Note
moderateDesloratadine + Venlafaxine
"The risk or severity of adverse effects can be increased when Desloratadine is combined with Venlafaxine."
Clinical Note
moderateDesloratadine + Nefazodone
"The risk or severity of adverse effects can be increased when Desloratadine is combined with Nefazodone."
Clinical Note
moderateDesloratadine + Stiripentol
"The risk or severity of adverse effects can be increased when Desloratadine is combined with Stiripentol."
Clinical Note
moderateTerminal half-life 12-24 hours (mean 18 hours); requires twice-daily dosing after initial titration.
Primarily renal (87% as metabolites, ~41% unchanged) and fecal (~9%). Metabolized to active 3-hydroxydesloratadine.
Renal (50-70% as conjugates, <2% unchanged), fecal (<10%), with enterohepatic circulation.
Category A/B
Category A/B
Antihistamine
Antihistamine / Mast Cell Stabilizer
Desloratadine + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Desloratadine."